Post-Approval Maintenance and Lifecycle Management via the International Recognition Procedure (IRP) in the United Kingdom: Experiences, Pitfalls and Benefits

The UK's IRP, launched following Brexit, is an increasingly important pathway for companies seeking to bring medicines to the UK market. It allows applicants to leverage prior approvals from trusted reference regulators – such as the European Medicines Agency (EMA), Food and Drug Administration (FDA), and agencies from Australia, Canada, Japan, Switzerland, and Singapore – while still navigating the UK's independent regulatory framework.

While the IRP is particularly attractive for initial marketing authorisations, its role in post-approval maintenance and lifecycle management is just as critical. Managing variations, extensions, and other lifecycle changes efficiently can significantly impact patient access and company operations. Here we explore real-world experiences, highlighting both pitfalls and benefits.

Pitfalls of Lifecycle Management via the IRP

Independent MHRA Decision Making

Unlike the centralised European procedures, the IRP does not guarantee automatic acceptance of a reference regulator's decision. The MHRA is explicit in its position: it will not simply rubber-stamp an outcome from another agency. This means that even if a lifecycle change – for example a label update, formulation change, or new manufacturing site – has been accepted by the EMA or FDA, the MHRA may still raise independent questions or refuse alignment.

This independence is both a strength and a challenge. It ensures the UK retains control over regulatory decisions, but it also introduces uncertainty and can disrupt expectations of smooth, copy-paste maintenance approvals. Companies must therefore budget time and resources for potential UK-specific requirements.

Divergence in Timelines and Requirements

Even when approvals are aligned, the MHRA's review timelines may not match those of the reference regulator. This creates operational complexity: global regulatory teams must plan staggered submissions, risk misalignment of implementation dates, and prepare for separate labelling or product lifecycle strategies in the UK.

Extensive Requirements

Since the IRP's introduction, both industry and the MHRA have undergone a learning curve in fully interpreting the procedural requirements. In the early stages, this sometimes led to assessment challenges, including validation correction requests and additional requests for information. However, as guidance has matured, companies have been able to refine their submission practices – for example by adapting templates for cover letters and supporting documentation to better meet MHRA expectations. The publication of the MHRA's IRP checklist has further streamlined the process, reducing avoidable issues and improving overall submission quality.

Benefits of Lifecycle Management via the IRP

A Simplified, Streamlined Route

Despite its pitfalls, the IRP provides a simplified route to approval compared with full UK national assessments. In practice, companies often encounter fewer and less complex questions, especially when changes are well-supported and have already undergone robust review by a trusted regulator. This reduces administrative burden and accelerates access to the UK market for post-approval changes.

Greater Predictability

For routine lifecycle changes – such as quality-related updates or minor labelling adjustments – the IRP pathway can be highly efficient and offers greater predictability compared with a standalone national assessment.

Practical Takeaways

• Plan for independence: do not assume the MHRA will agree with a proposed variation on the basis of another agency's approval.
• Factor in timing: be mindful of possible divergence in review timelines and plan UK submissions accordingly.
• Leverage IRP strategically: use the pathway where feasible to provide additional strength to your variation application.

The UK's post-Brexit regulatory landscape presents both opportunities and challenges that require specialist expertise. Our regulatory consultants have extensive experience guiding pharmaceutical companies through IRP submissions, variations, and lifecycle management strategies. Whether you're planning your first IRP variation or looking to optimise your UK regulatory approach, we can help you anticipate MHRA requirements, avoid common pitfalls, and maximise the benefits of this evolving pathway.